Lipocine is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 17 staff and has a trailing 12-month revenue of around $16.6 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.36 - $1.89 |
| 50-day moving average | $0.46 |
| 200-day moving average | $0.63 |
| Wall St. target price | $3.67 |
| PE ratio | 13.0125 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.04 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.521 from 2023-02-01
| 1 week (2023-01-26) | 0.19% |
|---|---|
| 1 month (2022-12-30) | 30.97% |
| 3 months (2022-11-02) | 29.41% |
| 6 months (2022-08-02) | -34.05% |
| 1 year (2022-02-01) | -49.90% |
|---|---|
| 2 years (2021-02-02) | -69.53% |
| 3 years (2020-01-31) | 18.06% |
| 5 years (2018-02-02) | 1.33 |
Valuing Lipocine stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lipocine's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lipocine's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Lipocine shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Lipocine's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.2 million.
The EBITDA is a measure of a Lipocine's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.6 million |
|---|---|
| Operating margin TTM | 19.45% |
| Gross profit TTM | $16.1 million |
| Return on assets TTM | 5.05% |
| Return on equity TTM | 11.62% |
| Profit margin | 24.69% |
| Book value | $0.43 |
| Market capitalisation | $46.1 million |
TTM: trailing 12 months
We're not expecting Lipocine to pay a dividend over the next 12 months.
Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.
Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.36 up to $1.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.7848. This would suggest that Lipocine's shares are less volatile than average (for this exchange).
Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.